3.2 C
New York
Wednesday, February 1, 2023

Concert Pharmaceuticals Inc. (CNCE): A Case For Going Higher

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Concert Pharmaceuticals Inc. (CNCE) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.40, or -5.63%, to $6.70. The Concert Pharmaceuticals Inc. has recorded 31,424 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $7.10 and fluctuated between $7.81 as its day high and $6.88 as its day low. The current market capitalization of Concert Pharmaceuticals Inc. is $285.42M. A total of 0.91 million shares were traded on the day, compared to an average of 431.68K shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CNCE has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 3,539 and the disposition of 3,539 shares. Over the last 12 months, there were 19 BUYs and 6 SELLs from insiders. Insiders purchased 914,091 shares during that period but sold 34,354.

In the most recent transaction, Tung Roger D sold 9,240 shares of CNCE for 7.24 per share on Jan 06. After the transaction, the Chief Executive Officer now owns 971,018 company shares. In a previous transaction on Jan 06, Stuart Nancy sold 2,893 shares at 7.25 per share. CNCE shares that Chief Operating Officer owns now total 281,844.

Among the insiders who sold shares, Munsie Jeffrey A disposed of 2,893 shares on Jan 06 at a per-share price of $7.25. This resulted in the Chief Legal Officer holding 100,304 shares of CNCE after the transaction. In another insider transaction, Cassella James V sold 2,893 shares at $7.25 per share on Jan 06. Company shares held by the Chief Development Officer now total 186,929.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CNCE in the last 3 months, the mean price target is $17.40 with high estimates of $25.00 and low estimates of $13.00. In terms of 52-week highs and lows, CNCE has a high of $7.90 and a low of $2.57.

As of this writing, CNCE has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.52 per share and a lower estimate of -$0.64. The company reported an EPS of -$1.03 in the last quarter, which was -13.20% lower than expectations of -$0.91.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CNCE is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles